Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 19/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 9/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | SRSF6 | Q13247 | 1/20 | 0.54 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.54 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4143547 | 1.00 | ADRB2 (0.62) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| SCHEMBL4132536 | 0.88 | ADRB2 (0.58) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| SCHEMBL4139870 | 0.88 | ADRB2 (0.57) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| SCHEMBL244696 | 0.83 | ADRB2 (0.80) | ADRB2ADRB1DRD3 | |
| SCHEMBL4889160 | 0.83 | ADRB2 (0.80) | ADRB2ADRB1DRD3 | |
| SCHEMBL4134392 | 0.80 | ADRB2 (0.57) | ADRB2ADRB1 | |
| SCHEMBL5127959 | 0.79 | ADRB2 (0.87) | ADRB2ADRB1DRD3 | |
| SCHEMBL3667231 | 0.79 | ADRB2 (0.80) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| SCHEMBL4134385 | 0.79 | ADRB2 (0.59) | ADRB2ADRB1 | |
| SCHEMBL4134389 | 0.79 | ADRB2 (0.59) | ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | claimed |
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885ADRB1 2/4885SLC6A2 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.